Advance radiopharmaceutical development with quantitative dosimetry and human dose prediction.
Understanding radiation exposure to healthy tissues is critical to developing safe and effective radiopharmaceutical therapies. Preclinical dosimetry studies provide the quantitative insights needed to assess potential toxicity, optimize therapeutic dosing, and support clinical translation.
Perceptive Discovery combines quantitative molecular imaging, biodistribution analysis, and advanced dosimetry modeling to help researchers make informed decisions throughout radiopharmaceutical development.
What You’ll Learn
Download our Preclinical Dosimetry Studies flyer to explore:
- Advanced dosimetry modeling: Human absorbed dose estimation using OLINDA 2.2.3 and specialized alpha- and beta-emitter modeling approaches.
- Biodistribution and imaging integration: Combining PET/SPECT imaging, gamma counting, and time-activity curve analysis to support quantitative dose calculations.
- Radionuclide translation: Applying surrogate isotope strategies, including Pb-203 to Pb-212, to support therapeutic development.
- Specialized dosimetry applications: Sub-organ kidney dosimetry, red marrow assessments, and intrathecal dose modeling.
- IND-enabling support: Generating quantitative dose estimates and reporting to inform regulatory submissions and first-in-human dose planning.
The flyer also includes a case study illustrating how Pb-203 biodistribution data can be translated into Pb-212 absorbed dose estimates.